Cabozantinib-d4
Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
Product Specifications
CAS Number
1802168-53-1
Product Name Alternative
XL184-d4; BMS-907351-d4
UNSPSC
12352005
Target
Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.04
Solubility
10 mM in DMSO
Smiles
COC(C(OC)=C1)=CC2=C1C(OC(C=C3)=CC=C3NC(C4(CC4)C(NC5=C([2H])C([2H])=C(C([2H])=C5[2H])F)=O)=O)=CC=N2
Molecular Formula
C28H20D4FN3O5
Molecular Weight
505.53
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16 (11) :2387-2398.|[3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10 (12), 2298-2308.|[4]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71 (14), 4758-4768.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GM-403-20 1 mL
Colloidal Gold Conjugated Sheep Affinity Purified Antibody to Rat IgG2c, 20nm
Sign In for Pricing
View Details 
